Histogenics Corp (NASDAQ:HSGX)’s stock price traded down 11.1% on Tuesday . The company traded as low as $0.23 and last traded at $0.24, 10,423,882 shares were traded during mid-day trading. An increase of 18% from the average session volume of 8,867,679 shares. The stock had previously closed at $0.27.

Separately, ValuEngine upgraded shares of Histogenics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

The firm’s 50-day moving average price is $0.21 and its two-hundred day moving average price is $0.18. The stock has a market cap of $25.44 million, a PE ratio of -0.31 and a beta of 3.10.

An institutional investor recently bought a new position in Histogenics stock. Geode Capital Management LLC bought a new position in shares of Histogenics Corp (NASDAQ:HSGX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 291,743 shares of the biotechnology company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned 0.47% of Histogenics as of its most recent SEC filing. 40.35% of the stock is currently owned by institutional investors and hedge funds.

Histogenics Company Profile (NASDAQ:HSGX)

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Read More: Momentum Indicators

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.